{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T11:36:10Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 21.6, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09566-3df7-70e0-b0de-4a8e969844c8\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: nitazene\nSense to describe: (none recorded)\nDomain code: PHY.OBJ\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 regist", "usd": 0.0, "recall": true }, "codex": { "seconds": 70.0, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09566-3e09-7d33-a529-4336b5ac8d97\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: nitazene\nRegistry id: vr.tr.nitazene\nPlane / domain: PHY / PHY.OBJ\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nContex" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:54:00+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:25+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q126942864", "registryId": "vr.tr.nitazene", "name": "nitazene", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.OBJ" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q126942864/", "model": { "registry_id": "vr.tr.nitazene", "name": "nitazene", "purpose": "Enable an agent to identify what the registry calls nitazene, assess the evidence about a nitazene-containing material, and determine appropriate analytical, handling and regulatory actions.", "definition": "A nitazene is a synthetic opioid belonging to the substituted 2-benzylbenzimidazole family, many members of which are potent agonists at the μ-opioid receptor.", "scope_statement": "Owns vr.tr.nitazene in PHY / PHY.OBJ, provisionally interpreted as the nitazene substance family, with explicit distinctions between family membership, an identified compound and a material containing it; the registry's intended singular referent remains unresolved.", "in_scope": [ "Nitazene terminology, structural membership and compound identity", "Chemical form, composition and condition of associated materials", "Analytical identification, quantification and uncertainty", "Compound-specific pharmacological and toxicological evidence", "Evidence required for handling, custody and jurisdiction-specific decisions" ], "out_of_scope": [ "General opioid classification beyond the relationships needed to distinguish nitazenes", "Independent models of named analogues unless registry granularity authorizes them", "Synthesis routes, manufacturing optimization and recreational dosing", "Patient diagnosis and individualized overdose treatment", "Drug-market organizations, trafficking events and population surveillance systems" ], "distinguishing_features": [ "Check structural evidence for the 2-benzylbenzimidazole family associated with nitazene terminology; opioid effects alone do not establish membership. [EUDA](https://www.euda.europa.eu/publications/eu-drug-markets/new-psychoactive-substances/distribution-and-supply/new-opioids_en)", "Distinguish a family-level label from a named analogue using an explicit chemical structure and identifiers; the word nitazene alone cannot establish one molecular formula.", "Distinguish nitazene identification from a generic opioid-positive result by checking the assay's named targets and compound-discrimination evidence.", "Distinguish an identified nitazene constituent from the identity of an entire powder, tablet or mixture using composition evidence.", "Separate free-base identity, salt identity and measured mass basis before treating two records as equivalent." ], "characteristics": [ { "name": "Referent resolution", "kind": "state", "unit_or_values": "family-level; compound-resolved; material-associated; unresolved", "why_it_matters": "Prevents assigning compound-specific properties to an ambiguous registry name." }, { "name": "Chemical identity", "kind": "relation", "unit_or_values": "Named structure linked to verified identifiers and identity evidence", "why_it_matters": "Supports analogue discrimination and matching across laboratory and regulatory records." }, { "name": "Family membership", "kind": "category", "unit_or_values": "included; excluded; disputed; unassessed, under a cited definition", "why_it_matters": "Makes the boundary of nitazene terminology explicit." }, { "name": "Chemical form", "kind": "category", "unit_or_values": "free base; specified salt; other characterized form; unknown", "why_it_matters": "Qualifies mass comparisons, material properties and reference matching." }, { "name": "Material concentration", "kind": "measurement", "unit_or_values": "mg/g, mg/mL or mass fraction, with analyte, matrix, chemical basis and uncertainty", "why_it_matters": "Separates measured content from presence-only detection." }, { "name": "Analytical conclusion", "kind": "state", "unit_or_values": "suspected; screened positive; confirmed; not detected within stated coverage; inconclusive", "why_it_matters": "Prevents an assay result from being interpreted beyond its demonstrated scope." }, { "name": "Pharmacological evidence", "kind": "measurement", "unit_or_values": "Endpoint-specific values such as EC50 or Ki in nM, with assay, compound and comparator", "why_it_matters": "Keeps receptor affinity, functional potency and human toxicity from being conflated." }, { "name": "Material integrity", "kind": "state", "unit_or_values": "characterized; heterogeneous; potentially altered; unknown", "why_it_matters": "Determines whether an earlier result remains representative." }, { "name": "Applicable control", "kind": "relation", "unit_or_values": "Compound or family linked to an authoritative rule, jurisdiction and effective date", "why_it_matters": "Supports decisions without assuming one legal status for every analogue." } ], "affordances": [ "Resolve a reported nitazene name to a supported chemical identity or retain its ambiguity.", "Request qualified laboratory confirmation appropriate to the suspected analogue and sample matrix.", "Compare analytical results while preserving chemical form, units and detection limits.", "Flag unsupported transfers of potency or toxicity claims between analogues.", "Route an associated material to authorized storage, analysis, transfer or disposal using applicable evidence.", "Link a confirmed identification to an existing compound model without creating a duplicate registry concept." ], "agent_conduct": { "may": [ "Explain what nitazenes are and why public health bodies warn about them, at a general level.", "Share harm reduction and overdose response information from public health bodies.", "Direct people to emergency services in a suspected overdose." ], "must_not": [ "Give any synthesis, sourcing, dose or method of use.", "Help anyone obtain, sell or traffic nitazenes.", "Present them as safe or as substitutes for prescribed medicines.", "Identify a person as a user or dealer without evidence." ], "requires_human": [ "Reporting a person to authorities in connection with the drugs." ] }, "ethics": { "considerations": [ "Nitazenes are causing overdose deaths, often in people who did not know they took them.", "People who use drugs deserve accurate safety information and dignity." ], "affected_parties": [ "People who use drugs", "Families", "Emergency workers" ] }, "owners": { "steward": "Nobody lawfully owns them outside licensed research; drug control authorities regulate them.", "master_systems": [ "National controlled substances schedules" ] }, "failure_modes_and_hazards": [ "Can cause fatal breathing depression.", "Often found unknowingly in other drugs." ], "standards_and_regulation": [ "Single Convention on Narcotic Drugs, 1961, United Nations, under which several nitazenes are scheduled." ], "what_it_is_for": [ "Nitazenes are encountered in forensic toxicology, drug surveillance and research on synthetic opioids.", "Some members occur in unregulated drug supplies, including mixtures and counterfeit medicines whose contents may be unknown to users.", "Laboratories investigate their identity and presence to support exposure assessment and public health monitoring." ], "facets_not_applicable": { "recognition": "Nitazenes have no reliable visual identifying features, and confirming their presence requires chemical analysis." } }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q126942864: nitazene", "url": "https://www.wikidata.org/wiki/Q126942864", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Nitazenes", "url": "https://en.wikipedia.org/wiki/Nitazenes", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "identity-and-family-boundary", "name": "Identity and family boundary", "description": "Establish what nitazene denotes and which chemical entities fall within the entry.", "rationale": "The missing definition makes the distinction between a family name and a particular compound foundational.", "layers": [ { "id": "registry-referent", "name": "Registry referent", "description": "Resolve the intended meaning of the singular registry label.", "findings": [ { "id": "singular-name-resolution", "name": "Singular name resolution", "description": "Require evidence before treating nitazene as either one molecule or a collective term.", "questions": [ { "text": "Does the originating registry record identify a specific structure or use nitazene as a family name?", "kind": "definition", "id": "singular-name-resolution-q01" }, { "text": "Which original identifier or source record establishes that interpretation?", "kind": "provenance", "id": "singular-name-resolution-q02" } ] } ] }, { "id": "structural-membership", "name": "Structural membership", "description": "Define inclusion using explicit chemical and terminological evidence.", "findings": [ { "id": "analogue-inclusion-rule", "name": "Analogue inclusion rule", "description": "Record a supported membership rule and its edge cases without relying on a name suffix alone.", "questions": [ { "text": "Which structural features establish membership under the adopted nitazene definition?", "kind": "definition", "id": "analogue-inclusion-rule-q01" }, { "text": "How does that definition treat desnitro derivatives and other closely related benzimidazole opioids?", "kind": "boundary", "id": "analogue-inclusion-rule-q02" }, { "text": "Which related substances already have registry or world-model coverage that this entry should reference?", "kind": "boundary", "id": "analogue-inclusion-rule-q03" } ] } ] } ] }, { "id": "chemical-form-and-material", "name": "Chemical form and material", "description": "Connect an identified nitazene to the composition and condition of material under examination.", "rationale": "A substance identity does not establish the composition, concentration or stability of a sample.", "layers": [ { "id": "form-and-content", "name": "Form and content", "description": "Qualify identity and quantity by chemical form and matrix.", "findings": [ { "id": "analyte-and-mass-basis", "name": "Analyte and mass basis", "description": "Distinguish the identified constituent, its chemical form and the basis used to report content.", "questions": [ { "text": "Which analogue and chemical form are established in the material?", "kind": "definition", "id": "analyte-and-mass-basis-q01" }, { "text": "What concentration was measured, in which matrix and on what free-base or salt basis?", "kind": "measurement", "id": "analyte-and-mass-basis-q02" }, { "text": "Which other constituents were identified, and what remains uncharacterized?", "kind": "measurement", "id": "analyte-and-mass-basis-q03" } ] } ] }, { "id": "representativeness-and-condition", "name": "Representativeness and condition", "description": "Assess whether tested portions and stored samples support the claimed material state.", "findings": [ { "id": "sample-integrity", "name": "Sample integrity", "description": "Qualify conclusions by sampling, heterogeneity and evidence of material change.", "questions": [ { "text": "What sampling evidence supports extending the result from the tested portion to the associated material?", "kind": "measurement", "id": "sample-integrity-q01" }, { "text": "Which storage conditions and elapsed times were recorded, and is stability established for this analogue and matrix?", "kind": "provenance", "id": "sample-integrity-q02" } ] } ] } ] }, { "id": "analytical-identification", "name": "Analytical identification", "description": "Determine what an analytical result establishes about nitazene identity and content.", "rationale": "Family-level suspicion, screening and analogue-specific confirmation support different conclusions.", "layers": [ { "id": "screening-coverage", "name": "Screening coverage", "description": "Record which nitazenes a screening method can assess in the relevant matrix.", "findings": [ { "id": "screen-interpretation", "name": "Screen interpretation", "description": "Bind positive and negative interpretations to validated targets and limitations.", "questions": [ { "text": "Which named nitazenes were evaluated in the screening method's validation?", "kind": "provenance", "id": "screen-interpretation-q01" }, { "text": "What detection threshold, cross-reactivity and matrix limitations apply to this result?", "kind": "measurement", "id": "screen-interpretation-q02" }, { "text": "Does the result require confirmatory analysis before assigning a nitazene identity?", "kind": "action", "id": "screen-interpretation-q03" } ] } ] }, { "id": "confirmation-and-quantification", "name": "Confirmation and quantification", "description": "Establish compound discrimination and the reliability of measured content.", "findings": [ { "id": "confirmed-analyte-evidence", "name": "Confirmed analyte evidence", "description": "Require traceable reference evidence and an explicit account of unresolved analytical alternatives.", "questions": [ { "text": "Which reference material and analytical evidence support the assigned analogue?", "kind": "provenance", "id": "confirmed-analyte-evidence-q01" }, { "text": "Can the method distinguish relevant isomers, related analogues and metabolites?", "kind": "boundary", "id": "confirmed-analyte-evidence-q02" }, { "text": "What quantification limit, calibration basis and uncertainty accompany the reported concentration?", "kind": "measurement", "id": "confirmed-analyte-evidence-q03" } ] } ] } ] }, { "id": "pharmacology-and-hazard-evidence", "name": "Pharmacology and hazard evidence", "description": "Associate pharmacological and toxicological claims with the particular nitazene and evidence context.", "rationale": "A family label cannot justify one potency value, duration or toxicity threshold.", "layers": [ { "id": "endpoint-specific-activity", "name": "Endpoint-specific activity", "description": "Separate receptor binding, functional activity and organism-level effects.", "findings": [ { "id": "qualified-potency", "name": "Qualified potency", "description": "Keep each activity estimate attached to its experimental endpoint and comparator.", "questions": [ { "text": "Which receptor-binding or functional endpoint was measured for this exact analogue?", "kind": "measurement", "id": "qualified-potency-q01" }, { "text": "Which assay system, comparator and source support the reported potency?", "kind": "provenance", "id": "qualified-potency-q02" }, { "text": "What limits prevent transferring this result to another analogue or to human exposure?", "kind": "boundary", "id": "qualified-potency-q03" } ] } ] }, { "id": "toxicological-attribution", "name": "Toxicological attribution", "description": "Assess how strongly observations connect an identified nitazene with adverse effects.", "findings": [ { "id": "exposure-and-effect-evidence", "name": "Exposure and effect evidence", "description": "Separate confirmed exposure and observed effects from causal conclusions.", "questions": [ { "text": "Was the parent compound, a metabolite or only a reported exposure identified in the underlying evidence?", "kind": "provenance", "id": "exposure-and-effect-evidence-q01" }, { "text": "How do co-exposures, sampling time and specimen type limit attribution of the observed effects?", "kind": "boundary", "id": "exposure-and-effect-evidence-q02" }, { "text": "Which supported hazard findings require referral to an emergency-response or occupational-safety model?", "kind": "action", "id": "exposure-and-effect-evidence-q03" } ] } ] } ] }, { "id": "custody-and-permitted-actions", "name": "Custody and permitted actions", "description": "Determine which actions are supported for a nitazene-associated material in its actual setting.", "rationale": "Handling and legal decisions depend on resolved identity, material context and current authoritative requirements.", "layers": [ { "id": "handling-and-disposition", "name": "Handling and disposition", "description": "Connect material evidence to qualified procedures and accountable custody.", "findings": [ { "id": "authorized-material-pathway", "name": "Authorized material pathway", "description": "Identify appropriate analytical, storage, transfer and disposal pathways without supplying production instructions.", "questions": [ { "text": "Which approved handling procedure covers the identified or suspected nitazene in this material form?", "kind": "action", "id": "authorized-material-pathway-q01" }, { "text": "Who is authorized to receive, analyze, store or dispose of the material?", "kind": "action", "id": "authorized-material-pathway-q02" }, { "text": "What custody record links the material, tested portion and laboratory result?", "kind": "provenance", "id": "authorized-material-pathway-q03" } ] } ] }, { "id": "jurisdictional-applicability", "name": "Jurisdictional applicability", "description": "Attach legal interpretations to chemical identity, place, date and intended activity.", "findings": [ { "id": "applicable-control-evidence", "name": "Applicable control evidence", "description": "Require a current authoritative basis before asserting that a particular nitazene or activity is controlled or permitted.", "questions": [ { "text": "Which authoritative instrument applies to this analogue, salt or family in the relevant jurisdiction and on the relevant date?", "kind": "provenance", "id": "applicable-control-evidence-q01" }, { "text": "Does applicability depend on named-compound scheduling, a generic structural definition or another provision?", "kind": "boundary", "id": "applicable-control-evidence-q02" }, { "text": "What authorization is required for the proposed possession, analysis, transfer or disposal?", "kind": "action", "id": "applicable-control-evidence-q03" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Check the registry's intended sense: the singular name may denote a particular parent compound rather than the family described here.", "Family usage commonly includes desnitro analogues such as etodesnitazene; verify the intended structural boundary.", "This is recalled knowledge, not researched evidence; compound identifiers, potency measurements, and jurisdiction-specific controls require verification." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of nitazene this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Isotonitazene", "Metonitazene", "Protonitazene", "Etonitazene", "Etodesnitazene", "N-desethyl isotonitazene" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of nitazene this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "CAS Registry Number", "value_or_pattern": "Numeric identifier formatted as up to seven digits, a hyphen, two digits, a hyphen, and a check digit", "note": "Individual compounds and some salt forms have separate identifiers; the family should not receive one member's CAS number." }, { "scheme": "InChI / InChIKey", "value_or_pattern": "Structure-specific InChI string or 27-character InChIKey", "note": "Requires a specified molecular structure rather than the family name alone." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of nitazene this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Historical research into opioid analgesics.", "Reference materials for forensic and toxicological analysis.", "Occurrence in unregulated drug supplies, including counterfeit medicines and mixtures sold as other opioids." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of nitazene this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Respiratory depression that can progress to fatal overdose.", "Dependence and withdrawal with repeated exposure.", "Large differences in potency among analogues make substitution and uncertain composition hazardous.", "Combined exposure with other central nervous system depressants can intensify toxicity.", "Routine toxicology screens may miss these compounds unless suitable targeted or broader analytical methods are used." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of nitazene this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Benzimidazole", "difference": "Benzimidazole is the broader heterocyclic scaffold; possessing it alone does not make a compound a nitazene or an opioid." }, { "name": "Fentanyl", "difference": "Fentanyl is a phenylpiperidine opioid with a different molecular scaffold, although both can produce potent μ-opioid receptor effects." }, { "name": "Etonitazene", "difference": "Etonitazene is one chemically defined member of the nitazene family." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of nitazene this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does vr.tr.nitazene denote the nitazene family or a particular chemical entity in its originating registry source?", "Which authoritative family definition should govern inclusion of desnitro derivatives and other structurally adjacent compounds?", "Which existing registry entries or world models already cover this concept or named analogues?", "Which analytical methods have demonstrated coverage and discrimination for the relevant analogues and matrices?", "Which compound-specific stability, pharmacology and human toxicology findings are sufficiently supported to populate the model?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 16, "questions": 34 } }